Cargando…

Subunits of ARID1 serve as novel biomarkers for the sensitivity to immune checkpoint inhibitors and prognosis of advanced non-small cell lung cancer

INTRODUCTION: Patients with advanced non-small cell lung cancer (NSCLC) benefit from treatment with immune checkpoint inhibitors (ICIs). Biomarkers such as programmed death-ligand 1 (PD-L1), the tumor mutational burden (TMB) and the mismatch repair (MMR) status are used to predict the prognosis of I...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sun, Dantong, Tian, Lu, Zhu, Yan, Wo, Yang, Liu, Qiaoling, Liu, Shihai, Li, Hong, Hou, Helei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7425138/ https://www.ncbi.nlm.nih.gov/pubmed/32791957 http://dx.doi.org/10.1186/s10020-020-00208-9

Ejemplares similares

ARID1A, ARID1B, and ARID2 Mutations Serve as Potential Biomarkers for Immune Checkpoint Blockade in Patients With Non-Small Cell Lung Cancer
por: Zhu, Guangsheng, et al.
Publicado: (2021)

The role of CD28 in the prognosis of young lung adenocarcinoma patients
por: Sun, Dantong, et al.
Publicado: (2020)

ARID1A serves as a receivable biomarker for the resistance to EGFR-TKIs in non-small cell lung cancer
por: Sun, Dantong, et al.
Publicado: (2021)

Nivolumab induced hyperprogressive disease in advanced esophageal squamous cell carcinoma
por: Sun, Dantong, et al.
Publicado: (2020)

ARID1A deficiency associated with MMR deficiency and a high abundance of tumor-infiltrating lymphocytes predicts a good prognosis of endometrial carcinoma
por: Sun, Dantong, et al.
Publicado: (2023)

Case Report: Primary and Acquired Resistance Mechanisms of Nimotuzumab in Advanced Esophageal Squamous Cell Carcinoma Revealed by Targeted Sequencing
por: Sun, Dantong, et al.
Publicado: (2020)

Pan-cancer analysis of ARID family members as novel biomarkers for immune checkpoint inhibitor therapy
por: Zhu, Yan, et al.
Publicado: (2022)

Identification of MET fusions as novel therapeutic targets sensitive to MET inhibitors in lung cancer
por: Sun, Dantong, et al.
Publicado: (2023)

Biomarkers to predict prognosis and response to checkpoint inhibitors
por: Yuasa, Takeshi, et al.
Publicado: (2017)

Primary resistance to first-generation EGFR-TKIs induced by MDM2 amplification in NSCLC
por: Sun, Dantong, et al.
Publicado: (2020)

Role of YES1 amplification in EGFR mutation‐positive non‐small cell lung cancer: Primary resistance to afatinib in a patient
por: Tao, Junyan, et al.
Publicado: (2020)

Epigenetic-related gene mutations serve as potential biomarkers for immune checkpoint inhibitors in microsatellite-stable colorectal cancer
por: Liu, Chao, et al.
Publicado: (2022)

ALK rearrangements as mechanisms of acquired resistance to osimertinib in EGFR mutant non‐small cell lung cancer
por: Hou, Helei, et al.
Publicado: (2021)

ZCCHC17 Served as a Predictive Biomarker for Prognosis and Immunotherapy in Hepatocellular Carcinoma
por: Liu, Fahui, et al.
Publicado: (2022)

Inflammatory biomarkers in assessing severity and prognosis of immune checkpoint inhibitor‐associated cardiotoxicity
por: Liang, Lin, et al.
Publicado: (2023)

The role of MDM2 amplification and overexpression in therapeutic resistance of malignant tumors
por: Hou, Helei, et al.
Publicado: (2019)

The safety and serious adverse events of approved ALK inhibitors in malignancies: a meta-analysis
por: Hou, Helei, et al.
Publicado: (2019)

Low level of ARID1A contributes to adaptive immune resistance and sensitizes triple‐negative breast cancer to immune checkpoint inhibitors
por: Chen, Xin‐Yu, et al.
Publicado: (2023)

Eosinophil as a biomarker for diagnosis, prediction, and prognosis evaluation of severe checkpoint inhibitor pneumonitis
por: Li, Yanlin, et al.
Publicado: (2022)

Ribonucleotide reductase small subunit M2 serves as a prognostic biomarker and predicts poor survival of colorectal cancers
por: Liu, Xiyong, et al.
Publicado: (2013)

Potential non-invasive biomarkers in tumor immune checkpoint inhibitor therapy: response and prognosis prediction
por: Song, Ruixia, et al.
Publicado: (2023)

The efficacy and safety of apatinib for refractory malignancies: a review and meta-analysis
por: Sun, Dantong, et al.
Publicado: (2018)

Microsatellite instability states serve as predictive biomarkers for tumors chemotherapy sensitivity
por: Ye, Taojun, et al.
Publicado: (2023)

FSIP2 can serve as a predictive biomarker for Clear Cell Renal Cell Carcinoma prognosis
por: Zhang, Yixiao, et al.
Publicado: (2020)

Predictive and sensitive biomarkers for thyroid dysfunctions during treatment with immune‐checkpoint inhibitors
por: Kurimoto, Chiaki, et al.
Publicado: (2020)

Lactate dehydrogenase D serves as a novel biomarker for prognosis and immune infiltration in lung adenocarcinoma
por: Zhang, Yu, et al.
Publicado: (2023)

LncRNAs serve as novel biomarkers for diagnosis and prognosis of childhood ALL
por: Huang, Xuanmei, et al.
Publicado: (2021)

Four Prognosis-Associated lncRNAs Serve as Biomarkers in Ovarian Cancer
por: Zheng, Jianfeng, et al.
Publicado: (2021)

Transketolase Serves as a Biomarker for Poor Prognosis in Human Lung Adenocarcinoma
por: Niu, Cong, et al.
Publicado: (2022)

Refractory solitary cervical lymph node metastasis after esophageal squamous cell carcinoma surgery and its successful treatment with immune checkpoint inhibitor: A case report and literature review
por: Song, Wenjing, et al.
Publicado: (2020)

SKA3 Serves as a Biomarker for Poor Prognosis in Kidney Renal Papillary Cell Carcinoma
por: Feng, Dechao, et al.
Publicado: (2021)

Dynamics of Serum Tumor Markers Can Serve as a Prognostic Biomarker for Chinese Advanced Non-small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors
por: Zhang, Zhibo, et al.
Publicado: (2020)

Spindle and kinetochore-associated complex subunit 3 could serve as a prognostic biomarker for prostate cancer
por: Feng, Dechao, et al.
Publicado: (2022)

SIRT2 expression exhibits potential to serve as a biomarker for disease surveillance and prognosis in the management of cervical cancer patients
por: Yang, Li-ping, et al.
Publicado: (2020)

Advancement in research and therapy of NF1 mutant malignant tumors
por: Tao, Junyan, et al.
Publicado: (2020)

SKA1/2/3 serves as a biomarker for poor prognosis in human lung adenocarcinoma
por: Chen, Cheng, et al.
Publicado: (2020)

An oxidative stress biomarkers predict prognosis in gastric cancer patients receiving immune checkpoint inhibitor
por: Deng, Guiming, et al.
Publicado: (2023)

Biomarkers for Immune Checkpoint Inhibitors in Melanoma
por: Kitano, Shigehisa, et al.
Publicado: (2018)

New biomarkers for checkpoint inhibitor therapy
por: Burdett, Nikki, et al.
Publicado: (2020)

Peripheral Blood Biomarkers for Early Diagnosis, Severity, and Prognosis of Checkpoint Inhibitor-Related Pneumonitis in Patients With Lung Cancer
por: Lin, Xinqing, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_isr49r6s0udsjdhm82madclsv7